HSBC Holdings
NRIX icon

HSBC Holdings’s Nurix Therapeutics NRIX Stock Holding History

HSBC Holdings’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-34,239
Closed -$315K – 3087
2025
Q3 		$315K Buy
34,239
+14,736
+76% +$153K ﹤0.01% 2314
2025
Q2 		$227K Buy
19,503
+3,408
+21% +$36.8K ﹤0.01% 2620
2025
Q1 		$189K Buy
16,095
+3,988
+33% +$66.7K ﹤0.01% 2636
2024
Q4 		$226K Buy
+12,107
New +$278K ﹤0.01% 2650
2024
Q3 		– Sell
-17,038
Closed -$350K – 3099
2024
Q2 		$350K Sell
17,038
-16,640
-49% -$259K ﹤0.01% 2177
2024
Q1 		$495K Sell
33,678
-33,645
-50% -$362K ﹤0.01% 2098
2023
Q4 		$699K Buy
67,323
+19,258
+40% +$132K ﹤0.01% 1916
2023
Q3 		$377K Buy
48,065
+13,736
+40% +$125K ﹤0.01% 2094
2023
Q2 		$347K Buy
34,329
+8,877
+35% +$90.5K ﹤0.01% 2091
2023
Q1 		$225K Buy
25,452
+1,707
+7% +$17.8K ﹤0.01% 2342
2022
Q4 		$260K Buy
23,745
+11,571
+95% +$140K ﹤0.01% 2635
2022
Q3 		$162K Buy
+12,174
New +$193K ﹤0.01% 2684
2022
Q2 		– Sell
-11,615
Closed -$165K – 3385
2022
Q1 		$165K Buy
+11,615
New +$206K ﹤0.01% 3031

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HSBC Holdings's NRIX Position: Q4 2025 in Review

HSBC Holdings sold out of Nurix Therapeutics (NRIX) in Q4 2025, closing a stake of 34,239 shares — an estimated $315K sold.

HSBC Holdings first reported a position in NRIX in Q1 2022 and held it in 13 quarters. The position peaked at $699K in Q4 2023. 182 funds tracked by Wall St. Rank hold NRIX as of Q4 2025.

  • HSBC Holdings reported no remaining Nurix Therapeutics position as of Q4 2025 after selling out during the quarter.
  • HSBC Holdings sold 34,239 Nurix Therapeutics shares in Q4 2025, an estimated $315K.
  • HSBC Holdings first reported a position in Nurix Therapeutics in Q1 2022 and held it in 13 quarters.
  • HSBC Holdings's Nurix Therapeutics position peaked at $699K in Q4 2023.
  • 182 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q4 2025.

Based on HSBC Holdings's 13F filing for Q4 2025, filed 6 Mar 2026.